Evidence map›Paper›PMID 41449915›Full record

ArticleInternational journal of cancer2026

Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases.

Klaus Rostgaard, Stephen Hamilton-Dutoit, Kristina L Lauridsen, Lisa Ottander, Trine L Plesner, Peter Hollander, Peter Brown, Lene Sjö, Christoffer Johansen, Peter Kamper and 9 more

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Klaus RostgaardDanish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-6220-9414
Stephen Hamilton-DutoitDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Kristina L LauridsenDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Lisa OttanderDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Trine L PlesnerDepartment of Pathology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
Peter HollanderDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Peter BrownDepartment of Haematology, University Hospital of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-6522-4086
Lene SjöDepartment of Pathology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
Christoffer JohansenDepartment of Oncology, University Hospital of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4384-206X
Peter KamperDepartment of Haematology, Aarhus University Hospital, Aarhus, Denmark.
Estrid HøgdallDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-4689-5658
Francesco d'AmoreDepartment of Haematology, Aarhus University Hospital, Aarhus, Denmark.
Lena SpechtDepartment of Oncology, University Hospital of Copenhagen, Copenhagen, Denmark.
Ruth F JarrettMRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
James D McKayGenetic Cancer Susceptibility Group, International Agency for Cancer Research, Lyon, France.
Martin HutchingsDepartment of Haematology, University Hospital of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-3873-1741
Lisa L HjalgrimDepartment of Paediatric and Adolescent Medicine, University Hospital of Copenhagen, Copenhagen, Denmark.
Ingrid GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0001-6158-3041
Henrik HjalgrimDanish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4436-6798

Funding

Børnecancerfonden 2019-5998Cancerfonden 22 2167 PjDanmarks Frie Forskningsfond 09-072164Kræftens Bekæmpelse R40-A2167NIH HHS 1001CA257679-01A1
6 · The paper itself

Abstract

Current epidemiological thinking is that classic Hodgkin lymphoma (cHL) comprises multiple aetiologically distinct disease entities that may in part be defined by either histological subtype or the presence of Epstein-Barr virus (EBV) in the malignant cells, or by both. This study aimed to advance our understanding of epidemiological differences between cHL subtypes, in particular EBV-positive and EBV-negative cHL. We retrospectively collected and EBV-typed 1992 cHL primary tumour tissues from among all 2811 patients diagnosed with incident HL in Denmark in the period 1990 through 2010 'Hodgkin lymphoma in Denmark' [HOLYDAN] project. Based on characteristics of retrieved samples combined with additional information from national registers, we projected nationwide age-, sex-, histology- and EBV-specific cHL incidence rates. The analyses demonstrated age- and sex-dependent variation in histology- and EBV-tumour status-specific cHL incidence rates, details of which yielded new aetiological clues. cHL incidence increased markedly around the age of puberty, irrespective of histological subtype and EBV status. The incidence of all subtypes of cHL increased with age after age 50 years, with the exception of EBV-negative nodular sclerosis cHL in females, which therefore showed a single peak in incidence and was higher than in males among young adults. These results were obtained in a small homogeneous population and might, therefore, only apply to rich, industrialised, Western populations. Nevertheless, we propose that puberty creates an immunological host environment conducive to cHL development irrespective of EBV status and histology, and that age-related decline in immune function facilitates the development of both EBV-positive and EBV-negative cHL.

Indexed as

Hodgkin DiseaseImmunosenescencePubertyAdolescentAdultAgedChildChild, PreschoolDenmarkEpstein-Barr Virus InfectionsFemaleHerpesvirus 4, HumanHumansIncidenceMaleMiddle AgedaetiologyEpstein–Barr virusHodgkin lymphomaimmune senescencepuberty

Identifiers

PMID41449915
PMCPMC12996757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.